DNA4Life's new report uses patients' DNA to avoid ADRs

The U.S. introduction of a comprehensive and affordable prescription, Pharmacogenetic, was recently unveiled by DNA4Life. "By securely and responsibly making access to personalized, quality data – and care – an affordable reality, DNA4Life has the potenti | File photo

DNA4Life introduced their Pharmacogenetic Report, which uses patients' DNA to predict their responses to
the most commonly prescribed medications, Tuesday.

"By securely and responsibly making access to personalized, quality data – and care – an affordable reality, DNA4Life has the potential to revolutionize drug therapy for the most common health conditions that are managed with medication," Richard Zimmer III, co-founder and CEO, DNA4Life, said. "Our differentiated and more comprehensive analysis will assist healthcare professionals in customizing a personalized treatment plan for their patients of all ages, ethnicities and genders – particularly those being treated for chronic conditions, like high cholesterol, depression, ADHD or pain."

Until now, physicians have relied almost exclusively on the trial-and-error approach to finding the right medication or combination of medications to effectively manage and control health conditions, costing patients, on average, $1,000 per year.

Worse yet, trial-and-error can lead to medication errors and/or serious – or even fatal – adverse drug reactions (ADRs). According to the U.S. Food and Drug Administration, ADRs are the 4th leading cause of death in the United States today.